Diabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches
|
|
- Brittany Parks
- 5 years ago
- Views:
Transcription
1 Diabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches Dr. David Wong Associate Professor Retina Specialist, Department of Ophthalmology & Vision Sciences, University of Toronto, Canada
2 Pathophysiology of DME/DR Diabetic retinopathy Damage to blood vessels in the retina Ischemia Reduced supply of oxygen to the retina Production of VEGF Process to restore the reduced retina oxygen supply Increased permeability of blood vessels Diabetic Macular Edema (DME) New vessel growth Proliferative Diabetic Retinopathy (PDR)
3 Pathophysiology of DME/DR Diabetic retinopathy Damage to blood vessels in the retina Ischemia Reduced supply of oxygen to the retina Production of VEGF Process to restore the reduced retina oxygen supply Increased permeability of blood vessels Diabetic Macular Edema (DME) New vessel growth Proliferative Diabetic Retinopathy (PDR)
4 DME: milestones in treatment Laser photocoagulation 1980s Intravitreal steroids 2000s 2010s Intravitreal anti-vegf Ranibizumab, Aflibercept, (Bevacizumab*) RESOLVE (2010) 1 DRCR.net (2010) 2 RESTORE (2011) 3 DA VINCI (2011) 4 VIVID 6 VISTA 6 RETAIN 7 Protocol T 8 Key anti- VEGF trials: Ranibizumab Aflibercept Aflibercept / Ranibizumab / (Bevacizumab) RISE (2012) 5 RIDE (2012) 5 *Off-label use 1. Massin P et al. Diabetes Care 2010; 33(11): Elman MJ et al. Ophthalmology 2010; 117(6): Mitchell P et al. Ophthalmology 2011; 118(4): Do DV et al. Ophthalmology 2011; 118(9): Nguyen QD et al. Ophthalmology 2012; 119(4): Korobelnik J.-F. et al., Ophthalmology 2014; 121(11): RETAIN study record detail. Available at clinicaltrials.gov/ct2/show/nct The DRCR.net. NEJM 2015; DOI: /NEJMoa
5 Proportion of eyes (%) with vision loss of 15 ETDRS letters ETDRS Macular laser photocoagulation Deferred laser treatment Macular laser reduced the risk of moderate vision loss by ~ 50% Conclusion: macular laser does not improve vision in CSME, but is effective at preserving vision/preventing further vision loss Time (months) ETDRS Research Group. Arch Ophthalmol. 1985;103:
6 Mean change in BCVA (ETDRS letters) Mean change in BCVA (ETDRS letters) RISE and RIDE RISE Ranibizumab 0.3 mg Ranibizumab 0.5 mg Sham/ranibizumab 0.5 mg RIDE At month 24, sham group crossed over to 0.5 mg ranibizumab Switched group did not achieve comparable improvements at month 36 to patients originally randomized to ranibizumab Time (months) Brown DM, et al. Ophthalmology. 2013;120(10): Nguyen QD et al. Ophthalmology 2012; 119(4):
7 Mean change in BCVA from baseline (ETDRS letters) VIVID / VISTA VIVID aflibercept PRN 1.6 Laser VISTA Primary endpoint q8* q4* q4* 9.4 2q8* 1.2 Laser 0.7 Laser q4* q4* q8* q8* 0.9 Laser 0.2 Laser Laser Aflibercept 2q4 Aflibercept 2q8 aflibercept PRN q8* q4* q8* q4* 1.4 Laser Week *P< vs. laser. Heier JS et al. Ophthalmology 2016; 123 (11):
8 Mean Change in Visual Acuity Letter Score DRCRnet: Protocol T Week Treatment Group Comparison*: Aflibercept vs. Bevacizumab P = 0.02 Aflibercept vs. Ranibizumab P = 0.47 Ranibizumab vs. Bevacizumab P = Weeks Aflibercept Bevacizumab Ranibizumab * P-values adjusted for baseline visual acuity and multiple comparisons
9 Proportion of patients with VA of 20/32 or better at Year 1 (%) Baseline VA is associated with VA outcomes at 1 year The relationships between various baseline characteristics and VA outcomes at 1 year following treatment with ranibizumab were analyzed in a DRCR.net study Patients with VA of 20/32 or better at Year /320 20/100 20/320-20/100 20/80-20/63 20/80 20/63 20/50 20/40 Baseline VA 75 n=69 n=79 n=63 n=65 Adapted from Bressler SB et al. (2012) supplementary table 2. Eyes with lower VA at baseline were more likely to achieve larger gains in VA but less likely to reach near-normal VA DRCR.net, Diabetic Retinopathy Clinical Research Network; VA, visual acuity. Bressler SB et al. Arch Ophthalmol 2012; 130 (9):
10 Mean number of injections Change from baseline in VA (letters) Sustained gains in VA with Ranibizumab with a reduced injection frequency long-term DRCR.net 1,2 Ranibizumab + deferred laser Ranibizumab + prompt laser DRCR.net 1,2 Ranibizumab + deferred laser Ranibizumab + prompt laser * Year 1 Year 2 Year Week Reduced injection frequency while average visual acuity gains at 6 months are maintained for at least 3 years Includes study participants completing the 3-year (156-week) visit
11 Mean change in visual acuity through 5 years following DRCR.net retreatment strategies And it does so with few injections after year 2! *Only eyes that completed 5-year visit 11
12 Pathophysiology of DME/DR Diabetic retinopathy Damage to blood vessels in the retina Ischemia Reduced supply of oxygen to the retina Production of VEGF Process to restore the reduced retina oxygen supply Increased permeability of blood vessels Diabetic Macular Edema (DME) New vessel growth Proliferative Diabetic Retinopathy (PDR)
13 PDR: milestones in treatment Laser photocoagulation Intravitreal anti-vegf Ranibizumab*, Aflibercept 1980s 2000s 2015s Ongoing DRCR.net : Protocol S CLARITY Key anti- VEGF trials: Ranibizumab Aflibercept *Off-label use Writing Committee for the Diabetic Retinopathy Clinical Research Network. JAMA 2015;314:
14 EVENT RATES/100 DRS - PDR LASER (PRP) 40 CONTROL (all visits) CONTROL (original protocol) TREATED (original protocol) TREATED (all visits) PRP superior to control (no treatment) Reduced severe visual loss by 50% Main treatment MONTHS OF FOLLOW-UP Ophthalmol 88: , 1981
15 DRCRnet: Protocol S Ranibizumab non-inferior to PRP Writing Committee for the Diabetic Retinopathy Clinical Research Network. JAMA 2015;314:
16 Diabetic retinopathy severity score (DRSS) Level ETDRS DRSS Description 1 10 DR absent 2 20 DR questionable, microaneurysms only 3 35 Mild NPDR 4 43 Moderate NPDR 5 47 Moderately severe NPDR 6 53 Severe NPDR 7 61 Mild PDR 2-step improvement in DRSS From DRSS 53, severe NPDR (Level 6) to DRSS Level 43, moderate NPDR (Level 4) 2-step improvement in DRSS From DRSS Level 53, severe NPDR (Level 6) 8 65 Moderate PDR 9 71 High-risk PDR High-risk PDR DR, diabetic retinopathy; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy. Davis MD et al. Invest Ophthalmol Vis Sci 1998; 39 (2):
17 ETDRS Va change from baseline All Cohorts RWE and RCT Real World Protocol T Vivid Vista Rise Ride Bevacizumab Ranibzumab Aflibercept Ciulla et a. :Presented ASRS 2017l.
18 Take away messages Anti VEGF superior but requires more frequent treatment /monitoring compared to laser Retinopathy can be regressed to an earlier stage Real World Evidence shows we undertreat Treating early leads to better outcomes: Patients should be educated and aware Referral process should be efficient Effective use of guidelines and protocols
19 Thank You
Outcomes of Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice
Outcomes of Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice John D. Pitcher, MD 1,2 ; Andrew A. Moshfeghi, MD 3 ; Genevieve Lucas, B. Comm. 4 ; Nick Boucher, BS 4
More informationPersistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment
9:30 AM Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment Lee Jampol, MD OBJECTIVE To assess subsequent visual and anatomic outcomes of eyes with
More informationDiabetic Retinopathy: Managing the Extremes. J. Michael Jumper, MD West Coast Retina
Diabetic Retinopathy: Managing the Extremes J. Michael Jumper, MD West Coast Retina Case 1: EC 65 y.o. HM No vision complaints Meds: Glyburide Metformin Pioglitazone Va: 20/20 OU 20/20 Case 2: HS 68 y.o.
More informationANTI-VEGF THERAPY FOR DIABETIC MACULAR EDEMA
January/February 2015 Supplement to ANTI-VEGF THERAPY FOR DIABETIC MACULAR EDEMA A roundtable discussion with Franck Fajnkuchen, MD, and Paolo Lanzetta, MD Case report by Paolo Lanzetta, MD The answers
More informationDiagnosis and treatment of diabetic retinopathy. Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City
Diagnosis and treatment of diabetic retinopathy Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City Disclosures Consulted for Novo Nordisk 2017,2018. Will be discussing
More informationDiabetic Macular Edema Treatment in the 21st Century
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationFront Line Diabetic Retinopathy What Not to Miss and Why
Front Line Diabetic Retinopathy What Not to Miss and Why David M Brown MD FACS Clinical Professor of Ophthalmology Blanton Eye Institute, Houston Methodist Hospital Baylor College of Medicine Retina Consultants
More information1/25/2018. Case Management Strategies in Diabetic Retinopathy. Case Study #1: Severe DME. DDOS: 3/31/2016 Va 20/400. Disclosures
Case Management Strategies in Diabetic Retinopathy Disclosures No financial conflict of interest Will discuss off label use of intraocular Bevacizumab (Avastin) for Diabetic Retinopathy Sundeep Dev, MD
More informationSupplement to March Ranibizumab for Visual Impairment in DME: An Overview of The Evidence SPONSORED BY NOVARTIS PHARMA AG
Supplement to March 2018 Ranibizumab for Visual Impairment in DME: An Overview of The Evidence SPONSORED BY NOVARTIS PHARMA AG Ranibizumab for Visual Impairment in DME: An Overview of The Evidence BY PROF.
More informationDiabetic Retinopatathy
Diabetic Retinopatathy Jay M. Haynie, OD, FAAO Financial Disclosure I have received honoraria or am on the advisory board for the following companies: Carl Zeiss Meditec Arctic DX Macula Risk Advanced
More informationNew Insights on Treating Diabetic Retinopathy & Diabetic Macular Edema from the 2018 AAO Meeting
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationThe Diabetic Retinopathy Clinical Research Network. Management of DME in Eyes with PDR
The Diabetic Retinopathy Clinical Research Network Management of DME in Eyes with PDR 1 What Has Been Learned? Diabetic Retinopathy Treatment Protocol F: Results suggest that clinically meaningful differences
More informationOverview of the Pathogenesis of Diabetic Retinopathy
Activity presentations are considered intellectual property. These slides may not be published or posted online without permission from Vindico Medical Education (cme@vindicocme.com). Please be respectful
More informationClinical Trials in Diabetic Retinopathy. Harry W. Flynn Jr., M.D. Nidhi Relhan Batra, M.D.
1 Clinical Trials in Diabetic Retinopathy 2018 Harry W. Flynn Jr., M.D. Nidhi Relhan Batra, M.D. Bascom Palmer Eye Institute 900 N.W. 17th Street Miami, FL 33136 Phone: (305) 326-6118 Fax: (305) 326-6417
More informationDiabetic Retinopathy Update 2017
Diabetic Retinopathy Update 2017 Basis for DR management standards for past 40 years Diabetic Retinopathy Study (DRS) 1971-1989 and Early Treatment of Diabetic Retinopathy Study (ETDRS) 1979-1990 Sundeep
More informationDr Dianne Sharp Ophthalmologist Retina Specialists, Parnell Greenlane Clinical Centre
Dr Dianne Sharp Ophthalmologist Retina Specialists, Parnell Greenlane Clinical Centre 11:00-11:55 WS #115: The Revolution in Macular Degeneration Management 12:05-13:00 WS #127: The Revolution in Macular
More informationReview Article Combination of Anti-VEGF and Laser Photocoagulation for Diabetic Macular Edema: A Review
Hindawi Ophthalmology Volume 2017, Article ID 2407037, 7 pages https://doi.org/10.1155/2017/2407037 Review Article Combination of Anti-VEGF and Laser Photocoagulation for Diabetic Macular Edema: A Review
More informationAnti Vascular Endothelial Growth Factor Pharmacotherapy for Diabetic Macular Edema
Ophthalmic Technology Assessment Anti Vascular Endothelial Growth Factor Pharmacotherapy for Diabetic Macular Edema A Report by the American Academy of Ophthalmology Allen C. Ho, MD, Ingrid U. Scott, MD,
More informationAn updated review of long-term outcomes from randomized controlled trials in approved pharmaceuticals for diabetic macular edema
Review Article An updated review of long-term outcomes from randomized controlled trials in approved pharmaceuticals for diabetic macular edema Jia-Kang Wang 1,2,3,4, Tzu-Lun Huang 1,5, Pei-Yuan Su 1,4,6,
More informationOutcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice
Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice Andrew A. Moshfeghi, MD, MBA 1 ; John D. Pitcher, MD 2,3 ; Genevieve Lucas, B. Comm. 4 ; Nick
More informationReview Article Combination Therapy for Diabetic Macular Edema
Ophthalmology Volume 2012, Article ID 484612, 6 pages doi:10.1155/2012/484612 Review Article Combination Therapy for Diabetic Macular Edema Dinah Zur and Anat Loewenstein Department of Ophthalmology, Tel
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 2Q17 April May
BRAND NAME Lucentis GENERIC NAME ranibizumab MANUFACTURER Genentech, Inc. DATE OF APPROVAL June 30, 2006 PRODUCT LAUNCH DATE July 13, 2006 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review of
More informationThe Era of anti- - - VEGF Kirk L. Halvorson, OD
The Era of anti- - - VEGF Kirk L. Halvorson, OD Introduction: Anti- - - Vascular Endothelial Growth Factor (Anti- - - VEGF) medication is a relatively a new line of medications used in treating a variety
More informationNew Developments in the treatment of Diabetic Retinopathy
New Developments in the treatment of Diabetic Retinopathy B. Jeroen Klevering University Medical Centre Nijmegen - The Netherlands Topics Management of diabetic retinopathy Interventions a. primary (prevention)
More informationEU Regulatory workshop Ophthalmology clinical development and scientific advice. Industry view on DME and macular edema secondary to RVO
EU Regulatory workshop Ophthalmology clinical development and scientific advice. Industry view on DME and macular edema secondary to RVO Yehia Hashad, M.D. Vice President and Global Therapeutic Area Head
More informationTREATMENT STRATEGIES FOR CHORIORETINAL VASCULAR DISEASES: ADVANTAGES AND DISADVANTAGES OF INDIVIDUALISED THERAPY
TREATMENT STRATEGIES FOR CHORIORETINAL VASCULAR DISEASES: ADVANTAGES AND DISADVANTAGES OF INDIVIDUALISED THERAPY *Michael W. Stewart Professor and Chairman, Mayo School of Medicine, Department of Ophthalmology,
More informationUpdates and Controversies
Updates and Controversies Philippine Journal of OPHTHALMOLOGY Vascular endothelial growth factor (VEGF) and inflammation. VEGF-A circulates normally in the body and is essential in endothelial cell growth.
More informationJay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington
Jay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington I Jay M. Haynie, OD, FAAO have received honoraria from the following companies: Reichert Technologies Notal Vision Carl Zeiss Meditec
More informationEvolution in Screening: Benefits of identifying and managing disease earlier
Evolution in Screening: Benefits of identifying and managing disease earlier Bora Eldem, Prof.,MD.,FEBO, Professor of Ophthalmology, Faculty of Medicine, Hacettepe University, Turkey Survey methodology
More informationDrugs vs. DME. Protocol T, the latest in a string of landmark studies by the Diabetic Retinopathy
3 Anti-VEGF Drugs vs. DME The latest study from DRCR.net delivers important clinical information, but questions remain. BY MIRIAM KARMEL, CONTRIBUTING WRITER alfred t. kamajian Protocol T, the latest in
More informationParadigm Shift in the treatment of Diabetic Retinopathy. Haytham I. S. Salti, MD Associate Professor
Paradigm Shift in the treatment of Diabetic Retinopathy Haytham I. S. Salti, MD Associate Professor Disclosure No financial interests related to the subject matter of this talk This presentation includes
More informationClinically Significant Macular Edema (CSME)
Clinically Significant Macular Edema (CSME) 1 Clinically Significant Macular Edema (CSME) Sadrina T. Shaw OMT I Student July 26, 2014 Advisor: Dr. Uwaydat Clinically Significant Macular Edema (CSME) 2
More informationPast ocular history. DME Case 1. Patient presents blurred VA. Hemoglobin A1c 11.5% -- patient states sugars have not been in good control
Past ocular history Patient presents blurred VA DME Case 1 Hemoglobin A1c 11.5% -- patient states sugars have not been in good control PDR with macular edema OU Rishi Singh MD Cleveland Clinic OD OS 1
More informationClinical Study Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy
Hindawi Ophthalmology Volume 2017, Article ID 5632634, 4 pages https://doi.org/10.1155/2017/5632634 Clinical Study Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF
More information8/8/17. Objectives. Proliferative Diabetic Retinopathy (PDR) Examining the Diabetic Patient: What Matters Most
Objectives Examining the Diabetic Patient: What Matters Most Jordan Keith, OD, FAAO Minneapolis, MN Simplify strategy for evaluating the eyes of diabetics Identify the threats to vision and treatments
More informationTargeting Inflammation in Diabetic Macular Edema: From Basic Science to Clinical Trials to Clinical Practice
Targeting Inflammation in Diabetic Macular Edema: From Basic Science to Clinical Trials to Clinical Practice Baruch D Kuppermann, MD, PhD Professor of Ophthalmology and Biomedical Engineering Director,
More informationIntravitreous injections of anti-vascular endothelial growth
Physiology and Pharmacology Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Adam
More informationEyes on Diabetics: How to Avoid Blindness in Diabetic Patient
Eyes on Diabetics: How to Avoid Blindness in Diabetic Patient Rova Virgana FK Unpad Pusat Mata Nasional RS Mata Cicendo Bandung Eye Center (Hospital and Clinic) PIT IDI Jabar 2018 Keys Facts from WHO
More informationPhiladelphia College of Osteopathic Medicine. Heather Bladek Philadelphia College of Osteopathic Medicine,
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2014 In Adult Patients With Diabetic Macular
More informationHHS Public Access Author manuscript J Vitreoretin Dis. Author manuscript; available in PMC 2017 November 03.
Prediction of Anti-VEGF Response in Diabetic Macular Edema After 1 Injection Ankoor R. Shah, M.D. 1,2, Yoshihiro Yonekawa, M.D. 3,7, Bozho Todorich, M.D. Ph.D. 3,7, Lily Van Laere, M.D. 3, Rehan Hussain,
More informationDiabetic Retinopathy Clinical Research Network
Diabetic Retinopathy Clinical Research Network Intravitreous Anti-VEGF Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk Version 4.0 September 19, 2017 Anti-VEGF
More informationFDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema
Investor Update Basel, 13 August 2012 FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema First Major Treatment Advance in More Than 25 Years for Sight-Threatening Condition
More informationRetina Diabetic Macular Edema
Retina Diabetic Macular Edema ILUVIEN A New Approach to the Treatment of Diabetic Macula Edema Pravin U Dugel, MD 1 and Richard Parrish, MD 2 1. Retinal Consultants of Arizona, Phoenix, Arizona, US; Clinical
More informationDiabetic eye disease. Diabetic retinopathy. Sam S. Dahr, M.D. Retina Center of Oklahoma.
Diabetic eye disease Sam S. Dahr, M.D. Retina Center of Oklahoma www.rcoklahoma.com Downloaded from: The Retina (on 28 May 2007 12:48 AM) 2007 Elsevier Diabetic retinopathy Downloaded from: The Retina
More informationReview Article Anti-VEGF for the Management of Diabetic Macular Edema
Immunology Research, Article ID 632307, 8 pages http://dx.doi.org/10.1155/2014/632307 Review Article Anti-VEGF for the Management of Diabetic Macular Edema Francisco Rosa Stefanini, 1,2 Emmerson Badaró,
More informationManagement of Retinal Disease: Advances in Treatment and Clinical Practice
Management of Retinal Disease: Advances in Treatment and Clinical Practice A Sponsored Supplement From The 3rd Global Retinal Network Program Annual Meeting May 20 21, 2017 Lisbon, Portugal The 3rd annual
More informationClinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME
Clinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME Ophthalmology Innovation Summit @ AAO, October 25 2018 Megan Baldwin PhD, CEO & Managing Director Disclaimer Investment
More informationMean Change in Visual Acuity Over 2 Years Baseline Visual Acuity 20/50 or Worse
DRCRnet Randomized Trial of Intravitreous Aflibercept versus Intravitreous Bevacizumab + Deferred Aflibercept for Treatment of Central-Involved DME: Protocol AC Chirag Jhaveri, MD 1 Background Aflibercept
More informationClinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME
Clinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME Ophthalmology Innovation Summit @ AAO, October 25 2018 Megan Baldwin PhD, CEO & Managing Director Disclaimer Investment
More informationTreatment pathways for Intravitreal therapies in Diabetic Macular Oedema (DMO) Louise Downey Consultant Ophthalmologist MBChB BSc PhD FRCOphth
Treatment pathways for Intravitreal therapies in Diabetic Macular Oedema (DMO) Louise Downey Consultant Ophthalmologist MBChB BSc PhD FRCOphth Disclosures and acknowledgements Financial disclosures; Alcon,
More informationNavilas Clinical Results: Diabetic Macular Edema Introducing a Better Treatment Paradigm for Patients and Physicians
Navilas Clinical Results: Diabetic Macular Edema Introducing a Better Treatment Paradigm for Patients and Physicians 16 % Injection-free after loading phase 65 % Injection-free after loading phase Navilas
More informationScott M. Pfahler D.O. Dayton Vitreo-Retinal Associates AOCOO-HNS Palm Springs, CA 2012
Scott M. Pfahler D.O. Dayton Vitreo-Retinal Associates AOCOO-HNS Palm Springs, CA 2012 Proliferative Diabetic Retinopathy Laser Treatments Medical Treatment Surgical Treatment Diabetic Macular Edema Laser
More informationComparative Evaluation of Combined Navigated Laser Photocoagulation and Intravitreal Ranibizumab in the Treatment of Diabetic Macular Edema
RESEARCH ARTICLE Comparative Evaluation of Combined Navigated Laser Photocoagulation and Intravitreal Ranibizumab in the Treatment of Diabetic Macular Edema OPEN ACCESS Citation: Liegl R, Langer J, Seidensticker
More informationCSME BCVA. OCT Bevacizumab CMT CMT BCVA. BCVA LogMAR. p CMT NPDR PDR PDR. Bevacizumab PDR FDA. Ranibizumab. Bevacizumab.
email: rezaj76@yahoo.com Bevacizumab FDA mg Ranibizumab - Bevacizumab NPDR PDR PDR PDR CSME FAZFA BCVA CMT OCT Bevacizumab BCVA CMT BCVA LogMAR p CMT p CSME CRVO CSME BRVO CRVOBRVO (fovea avascular zone)
More informationOpthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial
ASX and Media Release 3 January 2018 Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial Melbourne, Australia; January 3 2018 Opthea Limited (ASX:OPT), a late stage biopharmaceutical company
More informationCombination Therapy with Intravitreal Nesvacumab+Aflibercept in Diabetic Macular Edema: The Phase 2 RUBY Trial
Combination Therapy with Intravitreal Nesvacumab+Aflibercept in Diabetic Macular Edema: The Phase 2 RUBY Trial Jeffrey S. Heier, MD On behalf of the RUBY Investigators Ophthalmic Consultants of Boston
More informationVASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS
VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS FOR OPHTHALMIC USE Policy Number: 2016D0001B Effective Date: January 1, 2016 Table of Contents: Page: Cross Reference Policy: POLICY DESCRIPTION 2 ZALTRAP
More informationORIGINAL RESEARCH ARTICLE
EJO ISSN 1120-6721 Eur J Ophthalmol 2017; 27 (3): 357-362 DOI: 10.5301/ejo.5000929 ORIGINAL RESEARCH ARTICLE Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal
More informationAnti VEGF Agents in Retinal Disorders Current Scenario
Retina Anti VEGF Agents in Retinal Disorders Current Scenario Charu Gupta MS Charu Gupta MS, Cyrus M. Shroff MD Shroff Eye Centre, New Delhi T is a group of proteins involved in the regulation of angiogenesis,
More informationRetina 2014 Highlights and Hallmarks
Supplement to March 2015 CME ACTIVITY Retina 2014 Highlights and Hallmarks Rishi P. Singh, MD, Moderator Dean Eliott, MD Philip Ferrone, MD Szilárd Kiss, MD A CME activity jointly sponsored by The Dulaney
More informationILUVIEN IN DIABETIC MACULAR ODEMA
1 ILUVIEN IN DIABETIC MACULAR ODEMA Marie Tsaloumas Consultant Ophthalmic Surgeon Queen Elizabeth Hospital, Birmingham bars conference 2104 1 2 Declaration of interest I have sat on Advisory boards for
More informationOutcomes in Diabetic Macular Edema (DME) in Patients Who Used Systemic Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in the VISTA and VIVID trials
Outcomes in Diabetic Macular Edema (DME) in Patients Who Used Systemic Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in the VISTA and VIVID trials Ehsan Rahimy, MD 1 ; Keith Baker, MD 2 ; Desmond Thompson,
More informationBrampton Hurontario Street Brampton, ON L6Y 0P6
Diabetic Retinopathy What is Diabetic Retinopathy Diabetic retinopathy is one of the leading causes of blindness world-wide. Diabetes damages blood vessels in many organs of the body including the eyes.
More informationThere are no published randomized, double-blind trials comparing aflibercept to other therapies in neovascular AMD.
Subject: Eylea (aflibercept) Original Effective Date: 7/11/2014 Policy Number: MCP-191 Revision Date(s): 10/11/2016 Review Date(s): 12/16/2015; 10/11/2016, 6/22/2017, 7/10/2018 DISCLAIMER This Medical
More informationManagement of Neovascular AMD
Kapusta AMD Part 1 Management of Neovascular AMD Dr. Michael A. Kapusta, MD, FRCSC Ophthalmologist in Chief Jewish General Hospital Vitreoretinal Surgeon 1 FINANCIAL DISCLOSURES Consulting honoraria Bayer,
More informationDrug Class Update: Vascular Endothelial Growth Factors
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationFinancial Disclosures
Financial Disclosures DB is a scientific advisor for Regeneron/ Bayer and Genentech/ Roche & a DB member of the Regeneron Combination Products Steering Committee RCH receives grant support from Regeneron/
More informationCataract and Diabetic macular edema: What should I do?
Cataract and Diabetic macular edema: What should I do? Irini Chatziralli Ophthalmic Surgeon, University Scholar 2 nd Department of Ophthalmology, University of Athens (Director: Prof P. Theodossiadis)
More informationCharles C. Wykoff MD PhD Rahul N. Khurana MD
HDWallpapers Suprachoroidal Triamcinolone Acetonide with & without Intravitreal Aflibercept for DME: Results of the 6 Month Prospective Phase 1/2 Hulk trial Blanton Eye Institute Charles C. Wykoff MD PhD
More informationThe treatment of diabetic macular edema (DME) has become one of the most challenging management issues faced by ophthalmologists in
Review Retina The Value of Area Under the Curve Analysis as an Outcome Measure in the Assessment of a Continuous Microdosing Fluocinolone Acetonide Implant (ILUVIEN ) Sepehr Bahadorani 1 and Michael A
More informationFrom Outdated to Updated: A Review of Important Clinical Trials in Ocular Disease from 2014
From Outdated to Updated: A Review of Important Clinical Trials in Ocular Disease from 2014 1. This course is designed to review the important ophthalmic literature that was released between October 2013
More information12-month results of the standardised combination therapy for diabetic macular oedema: intravitreal bevacizumab and navigated retinal photocoagulation
Clinical science 1 Department of Ophthalmology, Jacobs Retina Center at Shiley Eye Center, University of California San Diego, La Jolla, CA, USA 2 Ophthalmological Unit, Department of Clinical Sciences
More informationTreatment practice in the
Strategies for managing neovascular AMD and in routine clinical care BY ROD MCNEIL Treatment practice in the management of neovascular age-related macular degeneration (AMD) and diabetic macular oedema
More informationARVO Annual Meeting, May 1, 2018, Honolulu, Hawaii
ARVO Annual Meeting, May 1, 2018, Honolulu, Hawaii A novel oral plasma kallikrein (PKal) inhibitor KV123833 blocks VEGF-mediated retinal vascular hyperpermeability in a murine model of retinal edema (#3464)
More informationClinical Trials in Diabetic Retinopathy. Harry W. Flynn Jr., M.D. Nidhi Relhan Batra, M.D.
1 Clinical Trials in Diabetic Retinopathy 2018 Harry W. Flynn Jr., M.D. Nidhi Relhan Batra, M.D. Bascom Palmer Eye Institute 900 N.W. 17th Street Miami, FL 33136 Phone: (305) 326-6118 Fax: (305) 326-6417
More informationSupplementary Online Content
Supplementary Online Content Avery RL, Gordon GM. Systemic safety of prolonged monthly anti vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis.
More informationLong-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant
Ophthalmol Ther (2015) 4:51 58 DOI 10.1007/s40123-015-0028-0 CASE REPORT Long-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant Thomas Bertelmann
More informationDiabetic retinopathy (DR) progressively
FOCUS ON DIABETIC MACULAR EDEMA * Frederick L. Ferris III, MD ABSTRACT The current state of treatment for diabetic macular edema (DME) is focused on slowing the rate of vision loss through assessment of
More informationREVIEW OF RECENT CLINICAL EVIDENCE ADDRESSING TREATMENT STRATEGIES AND OUTCOMES, INCLUDING MANAGEMENT OPTIONS FOR PATIENTS WITH DME
CME MONOGRAPH REVIEW OF RECENT CLINICAL EVIDENCE ADDRESSING TREATMENT STRATEGIES AND OUTCOMES, INCLUDING MANAGEMENT OPTIONS FOR PATIENTS WITH DME Highlights From Retina Edge Expert Roundtable Discussion
More informationEvolving Issues in Diabetic Vascular Complications: Understanding Ocular Manifestations
Supplement to January/February 2016 CME ACTIVITY Evolving Issues in Diabetic Vascular Complications: Understanding Ocular Manifestations John E. Anderson, MD Jay S. Duker, MD Allen C. Ho, MD John W. Kitchens,
More informationVisual Acuity Outcomes in Diabetic Macular Edema With Fluocinolone Acetonide 0.2 µg/day Versus Ranibizumab Plus Deferred Laser (DRCR Protocol I)
EXPERIMENTAL SCIENCE Visual Acuity Outcomes in Diabetic Macular Edema With Fluocinolone Acetonide 0.2 µg/day Versus Ranibizumab Plus Deferred Laser (DRCR Protocol I) Michael A. Singer, MD; Dan M. Miller,
More informationDiabetic Macular Oedema To treat or not to treat?
Diabetic Macular Oedema To treat or not to treat? Ms Ranjit Sandhu MBBS MRCOphth MD FRCOphth Consultant Ophthalmic Surgeon Cataract Surgery, Medical Retina & Uveitis The Luton and Dunstable University
More informationCURRENT TRENDS IN DIABETIC MACULAR EDEMA TREATMENT. Muge R. Kesen, MD
CURRENT TRENDS IN DIABETIC MACULAR EDEMA TREATMENT Muge R. Kesen, MD No relevant financial interest or relationships DISCLOSURE OBJECTIVES Current trends (evidence based) Review of clinical trials Diabetic
More informationCombination Treatment of Diabetic Macular Edema with Anti-Vascular Endothelial Growth Factor and Steroids: Analysis of DRCR.
REVIEW ARTICLE Combination Treatment of Diabetic Macular Edema with Anti-Vascular Endothelial Growth Factor and Steroids: Analysis of DRCR.net Protocol U Cindy Ung 1, Kareem Moussa 1, Yoshihiro Yonekawa
More informationTHE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION
THE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION MOESTIDJAB DEPARTMENT OF OPHTHALMOLOGY SCHOOL OF MEDICINE AIRLANGGA UNIVERSITY DR SOETOMO HOSPITAL SURABAYA INTRODUCTION
More informationCase Report Inherent Challenges in Managing Long Standing Refractory Diabetic Macular Edema
Cronicon OPEN ACCESS EC OPHTHALMOLOGY Case Report Inherent Challenges in Managing Long Standing Refractory Diabetic Macular Edema V Swetha E Jeganathan 1,2 * and Karen Madill 3 1 Department of Ophthalmology,
More informationClinical Trials Related to Age Related Macular Degeneration
Clinical Trials Related to Age Related Macular Degeneration Kirti Singh MD, DNB, FRCS Kirti Singh MD, DNB, FRCS, Pooja Jain MBBS, Nitasha Ahir MBBS, Divya Jain MD, DNB Guru Nanak Eye Centre, Maulana Azad
More informationDiabetic macular edema (DME) is a treatable sequela of diabetic retinopathy and a significant cause of visual morbidity among working
Update on the Management of Diabetic Macular Edema Shawn M Iverson 1 and W Lloyd Clark 1,2 1. Palmetto Health - University of South Carolina Medical Group, Columbia, South Carolina, US; 2. Assistant Clinical
More informationTreatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity
Diabetic Retinopathy Clinical Research Network Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity Version 3.0 April 18, 2014 Treatment of CIDME in Eyes with Good
More informationCurrent Insight Into Retinal Disease Management: Focus on DME and Intravitreal Corticosteroids
VIEW CASE VIDEOS ONLINE Supplement to March 2015 CME ACTIVITY Current Insight Into Retinal Disease Management: Focus on DME and Intravitreal Corticosteroids Allen C. Ho, MD, Moderator Michael D. Ober,
More informationClass Update: Vascular Endothelial Growth Factors
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationFaculty. Learning Objectives
Faculty H. Eric Cannon, PharmD, FAMCP Chief of Pharmacy SelectHealth Salt Lake City, Utah Rishi P. Singh, MD Staff Physician Cleveland Clinic Cole Eye Institute Associate Professor of Ophthalmology Case
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: The Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab,
More informationClinical Trials in Diabetic Retinopathy. Harry W. Flynn Jr., M.D. Nidhi Relhan, M.D.
1 Clinical Trials in Diabetic Retinopathy 2016 Harry W. Flynn Jr., M.D. Nidhi Relhan, M.D. Bascom Palmer Eye Institute 900 N.W. 17th Street Miami, FL 33136 Phone: (305) 326-6118 Fax: (305) 326-6417 E-mail:
More informationDiabetic maculopathy 11/ An update on. Miss Vasuki Sivagnanavel
Miss Vasuki Sivagnanavel Consultant Ophthalmologist An update on Diabetic maculopathy Despite advances in the management of diabetes, diabetic retinopathy is already the commonest cause of blindness among
More informationThe Posterior Segment in Diabetes
The Posterior Segment in Diabetes Course Goal! To provide useful clinical information about current standards in the treatment and management of diabetes and diabetic retinopathy. Carlo J. Pelino, OD,
More informationProtocol T and More for DR/DME IMPLICATIONS FOR PRACTICE
CME Monograph Protocol T and More for DR/DME IMPLICATIONS FOR PRACTICE Visit https://tinyurl.com/protocoltcme for online testing and instant CME certificate. FACULTY Dante J. Pieramici, MD (Program Chair
More informationDiabetic retinopathy (DR) is the leading PROCEEDINGS EVIDENCE-BASED DATA IN THE TREATMENT OF DIABETIC RETINOPATHY*
EVIDENCE-BASED DATA IN THE TREATMENT OF DIABETIC RETINOPATHY* Lloyd Paul Aiello, MD, PhD, and Jennifer K. Sun, MD, MPH ABSTRACT There is a wide array of research into the pathophysiology and treatment
More informationMacular edema (ME) is the most common
MANAGEMENT OF RETINAL VEIN OCCLUSIONS * Peter A. Campochiaro, MD ABSTRACT Macular edema (ME) is the most common cause of reduced vision in patients with retinal vein occlusions (RVOs). The primary cause
More informationDoes Ranibizumab Improve Best Corrected Visual Acuity in Adults with Diabetic Macular Edema Compared to Those without Ranibizumab?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2013 Does Ranibizumab Improve Best Corrected
More information